Omnicell, Inc. (NASDAQ:OMCL) Receives $37.83 Average PT from Analysts

Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $37.83.

OMCL has been the topic of a number of research analyst reports. Barclays raised Omnicell from an “underweight” rating to an “equal weight” rating and raised their price target for the company from $26.00 to $39.00 in a report on Friday, August 2nd. Bank of America boosted their price target on shares of Omnicell from $34.00 to $44.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Wells Fargo & Company increased their price objective on shares of Omnicell from $26.00 to $30.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. boosted their target price on Omnicell from $26.00 to $37.00 and gave the stock a “neutral” rating in a report on Friday, August 23rd. Finally, Benchmark restated a “buy” rating and issued a $38.00 target price on shares of Omnicell in a research report on Monday, July 15th.

Institutional Trading of Omnicell

Large investors have recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC lifted its position in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the last quarter. EntryPoint Capital LLC lifted its holdings in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after purchasing an additional 1,345 shares during the last quarter. CWM LLC boosted its position in shares of Omnicell by 68.2% in the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Benjamin Edwards Inc. increased its stake in Omnicell by 36.4% in the 1st quarter. Benjamin Edwards Inc. now owns 3,253 shares of the company’s stock worth $95,000 after purchasing an additional 868 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Omnicell during the 2nd quarter worth about $104,000. 97.70% of the stock is currently owned by institutional investors.

Omnicell Trading Down 1.7 %

Shares of NASDAQ:OMCL opened at $44.48 on Monday. Omnicell has a fifty-two week low of $25.12 and a fifty-two week high of $61.44. The company has a quick ratio of 2.22, a current ratio of 2.45 and a debt-to-equity ratio of 0.47. The company has a market cap of $2.05 billion, a PE ratio of -96.70, a P/E/G ratio of 49.29 and a beta of 0.80. The company’s 50-day moving average price is $33.97 and its 200 day moving average price is $30.55.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.51 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.37. Omnicell had a positive return on equity of 2.52% and a negative net margin of 1.92%. The company had revenue of $276.80 million for the quarter, compared to analysts’ expectations of $254.41 million. During the same quarter in the previous year, the company posted $0.29 earnings per share. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. Sell-side analysts anticipate that Omnicell will post 0.64 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.